利妥昔单抗/苯达莫司汀/阿糖胞苷治疗适合移植的套细胞淋巴瘤患者：一项回顾性研究。
Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.
机构信息
Department of Hematology, Toranomon Hospital, Tokyo, Japan.
Department of Hematology, Toranomon Hospital, Kajigaya, Japan.
出版信息
Cancer Med. 2023 Jun;12(11):12548-12552. doi: 10.1002/cam4.6114. Epub 2023 May 18.
BACKGROUND
Mantle cell lymphoma is considered an aggressive B-cell lymphoma. The optimal induction regimen remains controversial as no randomized controlled trial has compared the efficacy of different induction therapies.
METHOD
Herein, we performed a retrospective analysis of the clinical characteristics of 10 patients who received induction treatment consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and rituximab, bendamustine, and cytarabine (R-BAC) at Toranomon Hospital between November 2016 and February 2022.
RESULT
Although one patient discontinued R-BAC therapy due to a rash, the other nine completed the scheduled chemotherapy. All patients achieved complete response, underwent high-dose chemotherapy and autologous stem cell transplantation, and maintained complete remission with a median follow-up of 15 months. Hematological adverse events (AEs) occurred in all patients; however, none developed documented infection. There were also no fatal non-hematological AEs specific to R-BAC.
CONCLUSION
R-CHOP/R-BAC may be a good induction therapy for transplant-eligible patients with mantle cell lymphoma.
背景
套细胞淋巴瘤被认为是一种侵袭性 B 细胞淋巴瘤。由于没有随机对照试验比较过不同诱导疗法的疗效，因此最佳诱导方案仍存在争议。
方法
在此，我们对 2016 年 11 月至 2022 年 2 月在我院接受利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）和利妥昔单抗、苯达莫司汀和阿糖胞苷（R-BAC）诱导治疗的 10 例患者的临床特征进行了回顾性分析。
结果
尽管有 1 例患者因皮疹而停止 R-BAC 治疗，但其他 9 例患者均完成了预定的化疗。所有患者均达到完全缓解，接受了大剂量化疗和自体干细胞移植，中位随访 15 个月后均维持完全缓解。所有患者均发生血液学不良事件（AE）；然而，均未发生有记录的感染。也没有 R-BAC 特有的致命性非血液学 AE。
结论
R-CHOP/R-BAC 可能是适合移植的套细胞淋巴瘤患者的一种良好诱导治疗方法。
Zotero 插件